The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Pfizer has taken a $1.2 billion hit after reassessing the prospects of two antibody-drug conjugates (ADC) it picked up in the ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

CNW/ - This World Cancer Day, Pfizer Canada ULC, together with Rethink Breast Cancer, Colorectal Cancer Canada, Lung Health Foundation, Lung Cancer Canada, and the Quebec Lung Association, is pleased ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...